Ambrilia Biopharma, ZBx ink licensing pact
Under the agreement, ZBx can exercise its option during a period which starts 90 days from, and expires 120 days after, the effective date of the Option. If
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.